人乳头状瘤病毒疫苗:世界卫生组织2017年5月立场文件——建议
本文摘录世界卫生组织(WHO)2017年5月人乳头状瘤病毒(HPV)疫苗立场文件中的建议,该文件替代2014年版。文件聚焦宫颈癌预防,兼顾其他HPV相关癌症与疾病,纳入九价疫苗获批及疫苗效果新数据,并就仅女孩或女孩男孩均接种及多出生队列接种策略提出新建议。
要点
- WHO 2017年5月HPV疫苗立场文件替代2014年版,聚焦宫颈癌预防并兼顾其他HPV相关癌症与疾病。
- 文件纳入九价疫苗获批及疫苗效果新数据,并就疫苗选择提供指导。
- 文件就仅女孩或女孩男孩均接种及多出生队列接种策略提出新建议。
核心结论
- WHO立场文件主要聚焦宫颈癌预防,同时考虑可通过HPV疫苗接种预防的更广泛癌症和其他疾病。
研究设计与样本
- 本文为WHO立场文件建议摘录,由WHO发布,替代2014年WHO HPV疫苗立场文件。
- 建议于2016年10月由免疫战略咨询专家组(SAGE)讨论。
主要发现
- 文件纳入九价疫苗获批及疫苗效果新数据,并就疫苗选择提供指导。
- 文件就仅女孩或女孩男孩均接种及多出生队列接种策略提出新建议。
关键数值与推荐
- 文件脚注提供核心参考文献,包括评估科学证据质量的评级表及证据到建议表。
临床怎么用
- WHO立场文件主要关注大规模免疫规划中疫苗的使用,总结疾病与疫苗基本背景信息,并给出WHO在全球背景下对疫苗使用的当前立场。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This article presents the World Health Organization's (WHO) recommendations on the use of human papillomavirus (HPV) vaccines excerpted from the WHO position paper on Human papillomavirus vaccines: WHO position paper, May 2017, published in the Weekly Epidemiological Record [1]. This position paper replaces the 2014 WHO position paper on HPV vaccines [2]. The position paper focuses primarily on the prevention of cervical cancer, but also considers the broader spectrum of cancers and other diseases preventable by HPV vaccination. It incorporates recent developments concerning HPV vaccines, including the licensure of a nonavalent (9-valent) vaccine and recent data on vaccine effectiveness, and provides guidance on the choice of vaccine. New recommendations are proposed regarding vaccination strategies targeting girls only or both girls and boys, and vaccination of multiple birth cohorts [3]. Footnotes to this paper provide a number of core references including references to grading tables that assess the quality of the scientific evidence, and to the evidence-to-recommendation table. In accordance with its mandate to provide guidance to Member States on health policy matters, WHO issues a series of regularly updated position papers on vaccines and combinations of vaccines against diseases that have an international public health impact. These papers are concerned primarily with the use of vaccines in large-scale immunization programmes; they summarize essential background information on diseases and vaccines, and conclude with WHO's current position on the use of vaccines in the global context. Recommendations on the use of HPV vaccines were discussed by SAGE in October 2016; evidence presented at these meetings can be accessed at: www.who.int/immunization/sage/meetings/2016/october/presentations_background_docs/en/.
引用
- Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations. Vaccine. 2017. PMID: 28596091. doi:10.1016/j.vaccine.2017.05.069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。